HWHenrike Westekemper

Henrike Westekemper

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Henrike Westekemper has a total of 112 co-authors. Here are the top co-authors by number of shared publications:

  • Nikolaos Emmanouel Bechrakis

    Department of Ophthalmology, University Hospital Essen, University Duisburg-Essen, Hufelandstr. 55, 45147 Essen, Germany

    4 shared publications
  • Norbert Bornfeld

    Department of Ophthalmology, University Hospital Essen, University Duisburg-Essen, Duisburg, Germany

    4 shared publications
  • Anke Manthey

    Department of Ophthalmology, University Hospital Essen, Essen, Nordrhein-Westfalen, Germany

    3 shared publications
  • K.-P. Steuhl

    Klinik für Augenheilkunde, Universitätsklinikum Essen, Hufelandstr. 55, 45134, Essen, Deutschland

    3 shared publications
  • Klaus-Peter Steuhl

    Department of Ophthalmology, University Hospital Essen, Essen, Germany

    3 shared publications
  • Gerasimos Anastassiou

    Department of Ophthalmology, University Hospital Essen, Essen, Germany

    2 shared publications

Latest Publications

  • Open Access

    Long-Term Visual Acuity in Young Children After Lensectomy for Congenital Cataract

    by Caroline Glänzer, Sami Dalbah, Jan Strathmann, Mareile Knetsch, Anja Eckstein, Nikolaos E. Bechrakis, Henrike Westekemper, Mael Lever

    (1) Background: Congenital cataract is a rare but severe childhood ocular disorder that can lead to permanent visual impairment if left untreated. Factors influencing long-term visual outcomes are insufficiently defined. The aim of this study was to evaluate long-term visual outcomes after congenital cataract surgery and to identify factors associated with visual acuity impairment and reoperation rates. (2) Methods: This retrospective cohort study included 173 eyes of 116 patients who underwent surgery for congenital cataract at the University Hospital Essen between 2000 and 2018. Patients with a minimum postoperative follow-up of six years were included. Best-corrected visual acuity (BCVA) was analyzed according to binocular condition, age at surgery and the presence of comorbidities. Postoperative complications and the need for additional surgical interventions were evaluated. (3) Results: Unilateral cataract was present in 48% (n = 56) and bilateral cataract in 52% (n = 60) of patients. Age at surgery ranged from 2.1 weeks to 15.6 years in unilateral cases and from 3.1 weeks to 8.7 years in bilateral cases. Six years after surgery, mean BCVA was 1.0 logMAR (Snellen 20/200) in unilateral cases and 0.4 logMAR (Snellen 20/50) in bilateral cases. No significant association was found between long-term BCVA and either age at surgery or ocular or systemic comorbidities. Patients with microphthalmia and those born prematurely showed significantly higher rates of additional surgical procedures. (4) Conclusions: Bilateral cases of congenital cataract achieved a significantly better visual acuity than unilateral cases after surgery. In this cohort, neither age at surgery nor the presence of comorbidities was significantly associated with visual acuity, whereas microphthalmia and prematurity were linked to an increased likelihood of additional surgical interventions.

  • Open Access

    Metastatic disease in conjunctival malignant melanoma: a retrospective analysis of 167 cases

    by Melisa Sezgin, Ahmad Rahal, Veronika Nowack, Anke Manthey, Daniela Suesskind, Maja Guberina, Martin Stuschke, Dirk Flühs, Wolfgang A G Sauerwein, Klaus Griewank, et al.

    Objective: To analyse the data of a cohort of patients with conjunctival melanoma in order to analyse risk and guarding factors and to investigate the impact on metastatic disease with and without adjuvant therapy. Methods and analysis: We have retrospectively analysed the impact of clinical aspects and adjuvant therapies after tumour excision or biopsy in 167 patients cared for at the University Hospital Essen and the University Hospital Tübingen, Germany. Clinical as well as histopathological data and therapeutic approaches were analysed with regard to regional (lymphatic) and/or distant (haematogenous) spread during follow-up. The Kaplan-Meier estimate method was used to analyse survival and the Cox regression hazard model to define the probability of metastases depending on different factors. P value of = 0.003). 4 out of 54 patients developed distant metastases. Conclusion: In conjunctival melanoma, it is important to perform an adjuvant therapy after excision. This reduces not only local recurrences but also significantly the risk for haematopoietic spread.

  • Long-Term Results after Intraocular Surgery in Treated Retinoblastoma Eyes

    by Philipp Rating, Norbert Bornfeld, Sabrina Schlüter, Henrike Westekemper, Tobias Kiefer, Martin Stuschke, Sophia Göricke, Petra Ketteler, Saskia Ting, Klaus A. Metz, et al.

    Introduction: The aim of the study was to analyze the results of intraocular surgery in treated retinoblastoma eyes and to assess the long-term results with a priority on local recurrences, secondary enucleation, and metastases. Methods: Retrospective noncomparative case series. Results: From March 1964 to January 2020, 42 eyes of 40 retinoblastoma patients underwent intraocular surgery. Time interval between the last therapy and surgery was 9.5 years (mean: 114 months; median: 54.5 months). 31 eyes were treated for radiogenic cataract formation with a gain in visual acuity of 61.3%. One child developed an upper eyelid metastasis, 3 showed second primary malignancies (SPM), one a late recurrence, and 2 eyes were enucleated. Retinal surgery was performed in 17 eyes; 6 eyes were done as a combined procedure. Indications were radiogenic complications in the sense of a vitreous hemorrhage in 11 eyes and a rhegmatogenous retinal detachment in 6 eyes. 41.2% of the treated eyes had a postoperative gain in visual acuity, whereas 9.5% of the eyes could not be preserved in the long term. Regarding systemic involvement 2 patients developed late recurrences and one a SPM. Conclusion: Surgical therapy in treated retinoblastoma is necessary in isolated cases. In our series, cataract surgery was a safe procedure with a good option of a significant increase in visual acuity. As expected, vitreoretinal treated eyes showed a limited gain in visual acuity, a higher risk of late recurrences, and a lower globe retention rate. Therefore, a careful indication and individual risk-benefit analysis are mandatory.


  • Genetic characterization of advanced conjunctival melanoma and response to systemic treatment

    by Georg C. Lodde, Philipp Jansen, Inga Möller, Antje Sucker, Jessica C. Hassel, Andrea Forschner, Julia Eckardt, Friedegund Meier, Lydia Reinhardt, Katharina C. Kähler, et al.


  • Konjunktivitis (engl. conjunctivitis)

    by Henrike Westekemper, Alexander A. Bialasiewicz

  • Open Access

    Feasibility of Proton Beam Therapy as a Rescue Therapy in Heavily Pre-Treated Retinoblastoma Eyes

    by Eva Biewald, Tobias Kiefer, Dirk Geismar, Sabrina Schlüter, Anke Manthey, Henrike Westekemper, Jörg Wulff, Beate Timmermann, Petra Ketteler, Stefan Schönberger, et al.

    Despite the increased risk of subsequent primary tumors (SPTs) external beam radiation (EBRT) may be the only therapeutic option to preserve a retinoblastoma eye. Due to their physical properties, proton beam therapy (PBT) offers the possibility to use the effectiveness of EBRT in tumor treatment and to decisively reduce the treatment-related morbidity. We report our experiences of PBT as rescue therapy in a retrospectively studied cohort of 15 advanced retinoblastoma eyes as final option for eye-preserving therapy. The average age at the initiation of PBT was 35 (14–97) months, mean follow-up was 22 (2–46) months. Prior to PBT, all eyes were treated with systemic chemotherapy and a mean number of 7.1 additional treatments. Indication for PBT was non-feasibility of intra-arterial chemotherapy (IAC) in 10 eyes, tumor recurrence after IAC in another 3 eyes and diffuse infiltrating retinoblastoma in 2 eyes. Six eyes (40%) were enucleated after a mean time interval of 4.8 (1–8) months. Cataract formation was the most common complication affecting 44.4% of the preserved eyes, yet 77.8% achieved a visual acuity of >20/200. Two of the 15 children treated developed metastatic disease during follow-up, resulting in a 13.3% metastasis rate. PBT is a useful treatment modality as a rescue therapy in retinoblastoma eyes with an eye-preserving rate of 60%. As patients are at lifetime risk of SPTs consistent monitoring is mandatory.


  • Benigne und maligne Bindehauttumoren in Diagnostik und Therapie

    by Henrike Westekemper, Anke Manthey, Nikolaos Bechrakis

    Bindehauttumoren betreffen in Diagnostik und Therapie alle Bereiche der augenärztlichen Praxis. Das beginnt mit der klinischen Kontrolle von Bindehautnävi und anderen benignen Tumoren, der Einschätzung von entzündlichen Pseudotumoren und ihrer Abgrenzung zu Präkanzerosen oder vernarbenden Erkrankungen und mündet in der hochspezialisierten und interdisziplinären Führung onkologischer Patienten mit Lymphomen, hochmalignen Melanomen oder invasiven Plattenepithelkarzinomen. The aim of this paper is to give an overview of different benign and malignant epibulbar tumors. Categories can be made of the age of manifestation (paediatric tumors versus tumors of adults), the originating cell types (squamous cell tumors, melanocytic tumors, lymphomas or germ cell tumors) or genesis (proliferative, infectious or degenerating tumors). Most epibulbar tumors show lesions on the conjunctiva or the cornea. These can be flesh coloured or pigmented efflorescences with leucoplakias or hyperkeratosis. Especially malignant tumors show atypical growth of blood vessels, are often prominent and can have ulcerations or bleeding. In case of tumor growth, change in pigmentations or atypical bleedings a malign tumor can be suspected. The diagnosis should be confirmed using histopathological evaluation after an incisional or excisional biopsy. Molecular pathologic techniques extend the diagnostic tools and have an implication on the therapy of metastatic tumors. Therapeutic options of the malignant tumors (apart from lymphomas) are chirurgical excision preferably with a no touch technique and afterwards an adjuvant therapy consisting of radiation or cryotherapy. A topical chemotherapy with Mitomycin C, 5-Fluorouracil or Interferon α2b can be effective to reduce persisting precancerosis and reduce recurrences. In case of a suspected malignant tumor it is advisable to refer the patient to an ophthalmo-oncologic center to plan and ensure interdisciplinary therapy. Publication Date: 10 August 2020 (online) Georg Thieme Verlag KG Stuttgart · New York


  • Benigne und maligne Bindehauttumoren in Diagnostik und Therapie

    by Henrike Westekemper, Anke Manthey, Nikolaos Bechrakis

    Zusammenfassung: Bindehauttumoren betreffen in Diagnostik und Therapie alle Bereiche der augenärztlichen Praxis. Das beginnt mit der klinischen Kontrolle von Bindehautnävi und anderen benignen Tumoren, der Einschätzung von entzündlichen Pseudotumoren und ihrer Abgrenzung zu Präkanzerosen oder vernarbenden Erkrankungen und mündet in der hochspezialisierten und interdisziplinären Führung onkologischer Patienten mit Lymphomen, hochmalignen Melanomen oder invasiven Plattenepithelkarzinomen.


  • Okuläre Graft-versus-Host-Disease

    by H. Westekemper, S. L. Scholz, H. Thomasen, C. Halfwassen, K.-P. Steuhl

    Die okuläre GvHD („graft versus host disease“; Transplantat-gegen-Wirt-Reaktion) nach allogener Blutstammzelltransplantation beinhaltet immunologisch getriggerte Gewebsveränderungen in vielen Bereichen des Auges und insbesondere der Augenoberfläche. Im Rahmen des Leitthemas wird hier besonders auf die Hornhautkomplikationen im Rahmen einer chronischen okulären GvHD eingegangen.


  • Operative Therapie und Bestrahlung konjunktivaler Melanome

    by H. Westekemper, D. Meller, R. Darawsha, S.L. Scholz, D. Flühs, K.-P. Steuhl, J. Hérault, J. Thariat, W. Sauerwein

    Die Strahlentherapie des Bindehautmelanoms hat in den vergangenen Jahren gegenüber weniger invasiven therapeutischen Ansätzen an Bedeutung gewonnen. Das liegt an den erheblichen Rezidivraten, die bei fehlender adjuvanter Therapie erzielt werden, und an der zunehmenden Verfügbarkeit adäquater strahlentherapeutischer Methoden. Damit können auch Tumore bestrahlt werden, die zuvor nicht organerhaltend therapiert werden konnten.